Logo image of BRZE

BRAZE INC-A (BRZE) Stock Fundamental Analysis

NASDAQ:BRZE - Nasdaq - US10576N1028 - Common Stock - Currency: USD

32.41  +1.08 (+3.45%)

After market: 32.41 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to BRZE. BRZE was compared to 281 industry peers in the Software industry. No worries on liquidiy or solvency for BRZE as it has an excellent financial health rating, but there are worries on the profitability. BRZE is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year BRZE was profitable.
BRZE had a positive operating cash flow in the past year.
BRZE had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: BRZE reported negative operating cash flow in multiple years.
BRZE Yearly Net Income VS EBIT VS OCF VS FCFBRZE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 0 -50M -100M

1.2 Ratios

The Return On Assets of BRZE (-11.91%) is worse than 61.92% of its industry peers.
With a Return On Equity value of -21.85%, BRZE perfoms like the industry average, outperforming 42.70% of the companies in the same industry.
Industry RankSector Rank
ROA -11.91%
ROE -21.85%
ROIC N/A
ROA(3y)-15.85%
ROA(5y)-15.52%
ROE(3y)-27.38%
ROE(5y)-29.17%
ROIC(3y)N/A
ROIC(5y)N/A
BRZE Yearly ROA, ROE, ROICBRZE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 -10 -20 -30 -40

1.3 Margins

With a Gross Margin value of 69.13%, BRZE perfoms like the industry average, outperforming 54.80% of the companies in the same industry.
In the last couple of years the Gross Margin of BRZE has grown nicely.
The Profit Margin and Operating Margin are not available for BRZE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.13%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.04%
GM growth 5Y1.88%
BRZE Yearly Profit, Operating, Gross MarginsBRZE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60

More info and screens

7

2. Health

2.1 Basic Checks

BRZE does not have a ROIC to compare to the WACC, probably because it is not profitable.
BRZE has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BRZE has been increased compared to 5 years ago.
There is no outstanding debt for BRZE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BRZE Yearly Shares OutstandingBRZE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
BRZE Yearly Total Debt VS Total AssetsBRZE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 4.68 indicates that BRZE is not in any danger for bankruptcy at the moment.
BRZE has a better Altman-Z score (4.68) than 70.46% of its industry peers.
There is no outstanding debt for BRZE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.68
ROIC/WACCN/A
WACC10.59%
BRZE Yearly LT Debt VS Equity VS FCFBRZE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 100M 200M 300M 400M 500M

2.3 Liquidity

A Current Ratio of 1.98 indicates that BRZE should not have too much problems paying its short term obligations.
BRZE has a better Current ratio (1.98) than 60.14% of its industry peers.
BRZE has a Quick Ratio of 1.98. This is a normal value and indicates that BRZE is financially healthy and should not expect problems in meeting its short term obligations.
BRZE has a Quick ratio of 1.98. This is in the better half of the industry: BRZE outperforms 60.14% of its industry peers.
Industry RankSector Rank
Current Ratio 1.98
Quick Ratio 1.98
BRZE Yearly Current Assets VS Current LiabilitesBRZE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

BRZE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 169.23%, which is quite impressive.
The Revenue has grown by 25.77% in the past year. This is a very strong growth!
Measured over the past years, BRZE shows a very strong growth in Revenue. The Revenue has been growing by 43.83% on average per year.
EPS 1Y (TTM)169.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%400%
Revenue 1Y (TTM)25.77%
Revenue growth 3Y35.6%
Revenue growth 5Y43.83%
Sales Q2Q%22.48%

3.2 Future

BRZE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 59.47% yearly.
The Revenue is expected to grow by 16.92% on average over the next years. This is quite good.
EPS Next Y92.02%
EPS Next 2Y81.59%
EPS Next 3Y74.31%
EPS Next 5Y59.47%
Revenue Next Year17.32%
Revenue Next 2Y17.11%
Revenue Next 3Y17.18%
Revenue Next 5Y16.92%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BRZE Yearly Revenue VS EstimatesBRZE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
BRZE Yearly EPS VS EstimatesBRZE Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 1.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 180.06 indicates a quite expensive valuation of BRZE.
BRZE's Price/Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Earnings ratio of 28.22, BRZE is valued quite expensively.
Based on the Price/Forward Earnings ratio of 93.77, the valuation of BRZE can be described as expensive.
BRZE's Price/Forward Earnings is on the same level as the industry average.
When comparing the Price/Forward Earnings ratio of BRZE to the average of the S&P500 Index (20.86), we can say BRZE is valued expensively.
Industry RankSector Rank
PE 180.06
Fwd PE 93.77
BRZE Price Earnings VS Forward Price EarningsBRZE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150

4.2 Price Multiples

BRZE's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 172.73
EV/EBITDA N/A
BRZE Per share dataBRZE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4 5

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BRZE does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as BRZE's earnings are expected to grow with 74.31% in the coming years.
PEG (NY)1.96
PEG (5Y)N/A
EPS Next 2Y81.59%
EPS Next 3Y74.31%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BRZE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRAZE INC-A

NASDAQ:BRZE (5/2/2025, 8:00:01 PM)

After market: 32.41 0 (0%)

32.41

+1.08 (+3.45%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)03-27 2025-03-27/amc
Earnings (Next)06-02 2025-06-02/amc
Inst Owners80.64%
Inst Owner Change0.17%
Ins Owners0.9%
Ins Owner Change0.08%
Market Cap3.39B
Analysts83.85
Price Target53.79 (65.97%)
Short Float %5.79%
Short Ratio3.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)324.65%
Min EPS beat(2)125.81%
Max EPS beat(2)523.5%
EPS beat(4)4
Avg EPS beat(4)268.84%
Min EPS beat(4)51.79%
Max EPS beat(4)523.5%
EPS beat(8)8
Avg EPS beat(8)157.27%
EPS beat(12)12
Avg EPS beat(12)112.62%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)0.79%
Min Revenue beat(2)0.59%
Max Revenue beat(2)0.98%
Revenue beat(4)4
Avg Revenue beat(4)0.85%
Min Revenue beat(4)0.59%
Max Revenue beat(4)0.98%
Revenue beat(8)8
Avg Revenue beat(8)1.81%
Revenue beat(12)12
Avg Revenue beat(12)2.1%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.45%
PT rev (3m)5.21%
EPS NQ rev (1m)28.81%
EPS NQ rev (3m)69.9%
EPS NY rev (1m)18.83%
EPS NY rev (3m)16.78%
Revenue NQ rev (1m)0.12%
Revenue NQ rev (3m)-0.5%
Revenue NY rev (1m)0.32%
Revenue NY rev (3m)0.32%
Valuation
Industry RankSector Rank
PE 180.06
Fwd PE 93.77
P/S 5.71
P/FCF 172.73
P/OCF 92.45
P/B 7.14
P/tB 7.65
EV/EBITDA N/A
EPS(TTM)0.18
EY0.56%
EPS(NY)0.35
Fwd EY1.07%
FCF(TTM)0.19
FCFY0.58%
OCF(TTM)0.35
OCFY1.08%
SpS5.67
BVpS4.54
TBVpS4.24
PEG (NY)1.96
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.91%
ROE -21.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.13%
FCFM 3.31%
ROA(3y)-15.85%
ROA(5y)-15.52%
ROE(3y)-27.38%
ROE(5y)-29.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.04%
GM growth 5Y1.88%
F-Score6
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 168.54%
Cap/Sales 2.87%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.98
Quick Ratio 1.98
Altman-Z 4.68
F-Score6
WACC10.59%
ROIC/WACCN/A
Cap/Depr(3y)240.58%
Cap/Depr(5y)230.69%
Cap/Sales(3y)3.47%
Cap/Sales(5y)3.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)169.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%400%
EPS Next Y92.02%
EPS Next 2Y81.59%
EPS Next 3Y74.31%
EPS Next 5Y59.47%
Revenue 1Y (TTM)25.77%
Revenue growth 3Y35.6%
Revenue growth 5Y43.83%
Sales Q2Q%22.48%
Revenue Next Year17.32%
Revenue Next 2Y17.11%
Revenue Next 3Y17.18%
Revenue Next 5Y16.92%
EBIT growth 1Y15.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year753.67%
EBIT Next 3Y199.01%
EBIT Next 5Y123.55%
FCF growth 1Y402.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y435.47%
OCF growth 3YN/A
OCF growth 5YN/A